112 related articles for article (PubMed ID: 8045754)
1. Long-term intravenous deferoxamine treatment for noncompliant transfusion-dependent beta-thalassemia patients.
Tamary H; Goshen J; Carmi D; Yaniv I; Kaplinsky C; Cohen IJ; Zaizov R
Isr J Med Sci; 1994 Aug; 30(8):658-64. PubMed ID: 8045754
[TBL] [Abstract][Full Text] [Related]
2. Intensification of chelating-therapy in patients with thalassemia major.
Laws HJ; Göbel U; Christaras A; Janssen G
Klin Padiatr; 2005; 217(3):120-5. PubMed ID: 15858702
[TBL] [Abstract][Full Text] [Related]
3. Intravenous chelation therapy during transplantation for thalassemia.
Gaziev D; Giardini C; Angelucci E; Polchi P; Galimberti M; Baronciani D; Erer B; Maiello A; Lucarelli G
Haematologica; 1995; 80(4):300-4. PubMed ID: 7590497
[TBL] [Abstract][Full Text] [Related]
4. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration.
Lombardo T; Ferro G; Frontini V; Percolla S
Am J Hematol; 1996 Jan; 51(1):90-2. PubMed ID: 8571945
[TBL] [Abstract][Full Text] [Related]
5. A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia.
Pakbaz Z; Fischer R; Treadwell M; Yamashita R; Fung EB; Calvelli L; Quirolo K; Foote D; Harmatz P; Vichinsky EP
Ann N Y Acad Sci; 2005; 1054():486-91. PubMed ID: 16339703
[TBL] [Abstract][Full Text] [Related]
6. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
Giardina PJ; Grady RW
Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of the efficacy of chelation therapy with deferoxamine in patients with thalassemia major].
Rodríguez Galindo C; Ortega Aramburu JJ; Alonso JL; Albisu M; Casaldáliga J; Díaz de Heredia C; Olivé T; Bastida P
Med Clin (Barc); 1994 May; 102(19):721-4. PubMed ID: 8041200
[TBL] [Abstract][Full Text] [Related]
8. [Therapeuetic management of patients with thalassemia major].
Thuret I
Bull Soc Pathol Exot; 2001 May; 94(2):95-7. PubMed ID: 11475036
[TBL] [Abstract][Full Text] [Related]
9. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections.
Wali YA; Taqi A; Deghaidi A
Pediatr Hematol Oncol; 2004; 21(5):453-60. PubMed ID: 15205089
[TBL] [Abstract][Full Text] [Related]
10. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
Shalitin S; Carmi D; Weintrob N; Phillip M; Miskin H; Kornreich L; Zilber R; Yaniv I; Tamary H
Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
[TBL] [Abstract][Full Text] [Related]
11. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
[TBL] [Abstract][Full Text] [Related]
12. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.
Wolfe L; Olivieri N; Sallan D; Colan S; Rose V; Propper R; Freedman MH; Nathan DG
N Engl J Med; 1985 Jun; 312(25):1600-3. PubMed ID: 4000198
[TBL] [Abstract][Full Text] [Related]
13. Toxic effects of high-dose deferoxamine treatment in patients with iron overload: an electrophysiological study of cerebral and visual function.
Marciani MG; Cianciulli P; Stefani N; Stefanini F; Peroni L; Sabbadini M; Maschio M; Trua G; Papa G
Haematologica; 1991; 76(2):131-4. PubMed ID: 1937171
[TBL] [Abstract][Full Text] [Related]
14. Long term audiological evaluation of beta-thalassemic patients.
Kontzoglou G; Koussi A; Economou M; Tsatra I; Perifanis V; Noussios G; Athanassiou-Metaxa M
Acta Otorhinolaryngol Belg; 2004; 58(2):113-7. PubMed ID: 15515654
[TBL] [Abstract][Full Text] [Related]
15. Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator.
Harmatz P; Grady RW; Dragsten P; Vichinsky E; Giardina P; Madden J; Jeng M; Miller B; Hanson G; Hedlund B
Br J Haematol; 2007 Aug; 138(3):374-81. PubMed ID: 17614825
[TBL] [Abstract][Full Text] [Related]
16. Central venous line thrombosis in children and young adults with thalassemia major.
Finkelstein Y; Yaniv I; Berant M; Zilber R; Garty BZ; Epstein O; Lahav J; Tamary H
Pediatr Hematol Oncol; 2004; 21(5):375-81. PubMed ID: 15205080
[TBL] [Abstract][Full Text] [Related]
17. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre.
Gamberini MR; De Sanctis V; Gilli G
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():158-69. PubMed ID: 19337172
[TBL] [Abstract][Full Text] [Related]
18. Sensory neural hearing loss in beta-thalassemia major patients treated with deferoxamine.
Shamsian BS; Aminasnafi A; Moghadassian H; Gachkar L; Arzanian MT; Alavi S; Esfehani H; Garallahi F; Amini R
Pediatr Hematol Oncol; 2008 Sep; 25(6):502-8. PubMed ID: 18728969
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneous bolus injection of deferoxamine is an alternative method to subcutaneous continuous infusion.
Yarali N; Fişgin T; Duru F; Kara A; Ecin N; Fitoz S; Erden I
J Pediatr Hematol Oncol; 2006 Jan; 28(1):11-6. PubMed ID: 16394886
[TBL] [Abstract][Full Text] [Related]
20. [Arrhythmia in thalassemia major: evaluation of iron chelating therapy by dynamic ECG].
Cavallaro L; Meo A; Busà G; Coglitore A; Sergi G; Satullo G; Donato A; Calabrò MP; Miceli M
Minerva Cardioangiol; 1993; 41(7-8):297-301. PubMed ID: 8233011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
